Payment overview · 2025
General Payments
$858.41
17 reported records · 9 companies
Healthcare provider profile · identity verified
Tomas A Sevilla, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · LOS ANGELES, CA · NPI 1922189125
Verified facts
What the public records show
CMS Open Payments records show Tomas A Sevilla, M.D. received $858.41 in general payments during 2025 across 17 reported records.
Amgen Inc. accounted for 20.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $175.00 | 20.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $158.16 | 18.4% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $155.87 | 18.2% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $142.82 | 16.6% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $125.00 | 14.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $47.65 | 5.5% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.13 | 2.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.13 | 2.0% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.65 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $683.41 | 16 |
| Consulting Fee | $175.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $175.00 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $158.16 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $142.82 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $110.07 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $47.65 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $47.65 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $43.89 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $26.57 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $26.57 | 1 | 2025 |
Source payment records
|
|||||
| ID NOW INSTRUMENT Normalized: id now instrument |
Device | Abbott Laboratories | $20.13 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.13 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $16.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
23 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 151 | 68 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 133 | 66 |
| Amlodipine Besylate | Amlodipine Besylate | 122 | 50 |
| Losartan Potassium | Losartan Potassium | 121 | 47 |
| Omeprazole | Omeprazole | 104 | 38 |
| Metformin Hcl | Metformin Hcl | 102 | 49 |
| Celecoxib | Celecoxib | 99 | 56 |
| Levothyroxine Sodium | Levothyroxine Sodium | 87 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 79 | 33 |
| Metformin Hcl Er | Metformin Hcl | 73 | 31 |
| Benazepril Hcl | Benazepril Hcl | 66 | 22 |
| Glipizide | Glipizide | 61 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 33 |
| Montelukast Sodium | Montelukast Sodium | 55 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 54 | 25 |
| Enalapril Maleate | Enalapril Maleate | 49 | 18 |
| Lisinopril | Lisinopril | 45 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 45 | 12 |
| Azithromycin | Azithromycin | 44 | 43 |
| Diclofenac Sodium | Diclofenac Sodium | 43 | 32 |
| Finasteride | Finasteride | 43 | 17 |
| Simvastatin | Simvastatin | 40 | 16 |
| Alendronate Sodium | Alendronate Sodium | 39 | 13 |
| Gabapentin | Gabapentin | 37 | 19 |
| Prednisone | Prednisone | 37 | 34 |
| Sertraline Hcl | Sertraline Hcl | 37 | 20 |
| Famotidine | Famotidine | 33 | 20 |
| Ibu | Ibuprofen | 33 | 25 |
| Ibuprofen | Ibuprofen | 33 | 28 |
| Trazodone Hcl | Trazodone Hcl | 33 | 20 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 31 | 19 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 31 | 13 |
| Ozempic | Semaglutide | 30 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 27 | 15 |
| Telmisartan | Telmisartan | 27 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 26 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | 12 |
| Farxiga | Dapagliflozin Propanediol | 23 | 11 |
| Pantoprazole Sodium | Pantoprazole Sodium | 23 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 23 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 22 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 20 |
| Lorazepam | Lorazepam | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 17 | suppressed |
| Furosemide | Furosemide | 17 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Carvedilol | Carvedilol | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 15 |
| Lactulose | Lactulose | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | 11 |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 15 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Eliquis | Apixaban | 12 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Easy Glide Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Insulin Glargine Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $858.41 · 17 records | Amgen Inc. | AIRSUPRA, CREON, ID NOW INSTRUMENT, LINZESS, Leqembi, MOUNJARO, Ozempic, PROLIA, QULIPTA, REXULTI, UBRELVY, VOQUEZNA, ZEPBOUND | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error